Last reviewed · How we verify

CarVeDilol-SR (Slow Release)

Seoul National University Bundang Hospital · FDA-approved active Small molecule

CarVeDilol-SR (Slow Release) is a Beta-blocker with alpha-1 blocking activity Small molecule drug developed by Seoul National University Bundang Hospital. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.

Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.

Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.

At a glance

Generic nameCarVeDilol-SR (Slow Release)
SponsorSeoul National University Bundang Hospital
Drug classBeta-blocker with alpha-1 blocking activity
TargetBeta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Carvedilol blocks beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and vasculature. The slow-release formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing. This combination of effects reduces cardiac oxygen demand, lowers blood pressure, and improves cardiac efficiency in heart failure and hypertension.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CarVeDilol-SR (Slow Release)

What is CarVeDilol-SR (Slow Release)?

CarVeDilol-SR (Slow Release) is a Beta-blocker with alpha-1 blocking activity drug developed by Seoul National University Bundang Hospital, indicated for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.

How does CarVeDilol-SR (Slow Release) work?

Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.

What is CarVeDilol-SR (Slow Release) used for?

CarVeDilol-SR (Slow Release) is indicated for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction, Angina pectoris.

Who makes CarVeDilol-SR (Slow Release)?

CarVeDilol-SR (Slow Release) is developed and marketed by Seoul National University Bundang Hospital (see full Seoul National University Bundang Hospital pipeline at /company/seoul-national-university-bundang-hospital).

What drug class is CarVeDilol-SR (Slow Release) in?

CarVeDilol-SR (Slow Release) belongs to the Beta-blocker with alpha-1 blocking activity class. See all Beta-blocker with alpha-1 blocking activity drugs at /class/beta-blocker-with-alpha-1-blocking-activity.

What development phase is CarVeDilol-SR (Slow Release) in?

CarVeDilol-SR (Slow Release) is FDA-approved (marketed).

What are the side effects of CarVeDilol-SR (Slow Release)?

Common side effects of CarVeDilol-SR (Slow Release) include Dizziness, Fatigue, Bradycardia, Hypotension, Hyperglycemia, Bronchospasm.

What does CarVeDilol-SR (Slow Release) target?

CarVeDilol-SR (Slow Release) targets Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor and is a Beta-blocker with alpha-1 blocking activity.

Related